

About IAVI



Translating science
into global health impact

IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Key program areas

IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we're doing to help solve them.

► HIV

In 2023, 1.3 million people acquired HIV, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

- Advance the next generation of vaccines to prevent HIV acquisition by pairing sophisticated science with community-rooted research.
- Develop injectable antibodies that can prevent HIV acquisition for as long as six months with one dose.
- Partner with Africa to end HIV through ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), funded by a cooperative agreement with the U.S. Agency for International Development through the U.S. President's Emergency Plan for AIDS Relief.

► Tuberculosis (TB)

About one quarter of the world's population is infected with the bacterium that causes TB; 10.6 million people are estimated to have developed TB disease in 2021, resulting in approximately 1.6 million deaths.

- Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

► Emerging Infectious Diseases

We need rapid, scalable vaccine technologies for diseases that pose public health and bio-terror threats.

- Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, and Sudan virus diseases.

► Novel technologies and platforms

IAVI seeks to maximize the impact of novel technologies throughout our research portfolio so that innovations reach people in LMICs.

- Leverage our scientific, clinical, and access functions to improve access to innovative health solutions across disease areas.

► Product Development Center

IAVI's PDC bridges the "valley of death" in biomedical innovation development to help advance promising candidates from laboratory to clinic.

- Support for 53 biologics candidates to date, out of which 25 advanced to clinical trials.

IAVI fast facts

More than 25 years of breakthrough vaccine and antibody research

~375 employees

Staff in seven countries:
India, Kenya, Netherlands,
South Africa, Uganda, U.K., U.S.

Labs in La Jolla, California;
Jersey City, New Jersey;
and Faridabad, India

2023 revenue: \$130.5M

Revenue breakdown:
53.6% governments;
44.1% foundations and individuals;
2.3% other sources

501(c)(3) nonprofit organization

Pipeline 2025–2027

IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges. Below is the pipeline as of February 2025. Go to iavi.org for the most updated list of [IAVI-led candidates](#) and [IAVI-supported candidates](#).

IAVI products in development													
Candidate	2025				2026				2027				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
HIV vaccine candidates	Germline targeting preclinical antigen research												
	Preclinical												
	rVSVΔG-Env-HIV												
	Preclinical												
Passive immunization against HIV via bnAbs	Triple antibody combination product												
	Preclinical												
Emerging infectious diseases vaccine candidates	rVSVΔG-LASV-GPC												
	Phase 1 (IAVI C102) / 2 (IAVI C105) / 2b (IAVI C111)												
	rVSVΔG-SEBOV-GP												
	Phase 1 (IAVI C108, C109)												
Tuberculosis (TB) vaccine candidates	rVSVΔG-MARV-GP												
	Preclinical												
	Phase 1 (IAVI C104)												
Tuberculosis (TB) vaccine candidates	MTBVAC**												
	Phase 2b (IAVI C113)												
	mRNA-encoded TB antigens												
	← Preclinical												

* Trial in adults and adolescents. Biofabri is leading clinical development of the candidate in infants (currently in a Phase 3 trial).

IAVI-supported candidates													
Candidate	2025				2026				2027				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
HIV vaccine candidates	BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum)												
	Ph 1 ← IAVI C107												
	BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum)												
	Ph 1 ← IAVI C110												
	GRAd networked T-cell epitope*												
	Phase 1 (IAVI C114)												
TB vaccine candidate	MTBVAC**												
	Phase 2a (HVTN605)												
Mini-protein for COVID-19 prophylaxis	IPD-52520												
	Preclinical												
	Phase 1 (IAVI C106)												

* Trial in people living with HIV and people living without HIV in Zimbabwe and South Africa. ReiThera is the vaccine contract development and manufacturing organization. Ragon Institute developed the networked epitope vaccine insert. Mutula Trust is the clinical lead.

** Trial in adults and adolescents living with and without HIV. Biofabri is leading clinical development of the candidate in infants (currently in a Phase 3 trial).

IAVI gratefully acknowledges the generous support provided by the following major funders



Biomedical Advanced Research and Development Authority (BARDA) | Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of November 2025